New treatment for osteosarcoma using an immunomodulating peptide
Official title: Development of an immunomodulating peptide as a therapy for osteosarcoma in canine and human
Funded at Pharmain Corporation · NIH-10931704 · Data updated 2026-11-12
This study is testing a new treatment made from a special peptide that could help kids and teens with osteosarcoma, a type of bone cancer, by boosting their immune response and possibly stopping the cancer from spreading, offering hope for better outcomes alongside current chemotherapy options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pharmain Corporation NIH-funded |
| Lab location | 1 site (Bothell, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $995,099 |
| NIH project number | 5R44CA278570-02 |
| Project ID | NIH-10931704 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are children and adolescents diagnosed with osteosarcoma, particularly those at risk of metastasis.
✕Less likely to help
Patients with osteosarcoma who have already undergone extensive treatment or those with non-responsive tumors may not benefit from this research.
What this research studies
This research focuses on developing a novel immunomodulating peptide aimed at treating osteosarcoma, a common bone cancer in children and adolescents. The approach involves using this peptide to enhance anti-tumor activity and potentially prevent metastasis, which is a significant challenge in current treatments. The research will evaluate the peptide's effectiveness both as a standalone therapy and in combination with existing chemotherapy regimens. Patients may benefit from a new treatment option that could improve survival rates and reduce the risk of cancer spreading.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly improves survival rates for children with osteosarcoma.
How similar studies have gone: Previous research has shown promising results with similar immunomodulating therapies in cancer treatment, indicating potential for success in this approach.
Where this research is happening
-
Pharmain Corporation
Bothell, United States Active
Researchers
- Principal investigator: Alfaro, Joshua — Pharmain Corporation
- Study coordinator: Alfaro, Joshua
Related research
Other NIH-funded projects on the same topics.
-
Understanding how bone cancer cells rely on certain pathways to grow in childhood osteosarcoma
This grant studies how specific cancer-related pathways in bone-forming cells drive osteosarcoma in children, with the aim of finding better treatments.
-
Histotripsy + immune boost to fight osteosarcoma
A new treatment idea combines a precise non-surgical ultrasound method with an immune-boosting compound to help fight bone cancer in people and dogs.
-
Genomically guided drug testing for osteosarcoma in patient-derived models
A precision approach tests new drugs on osteosarcoma models created from patients to find promising treatments for kids and teens.
-
New ways to stop osteosarcoma from spreading
Researchers are testing new approaches to block how osteosarcoma spreads, with the aim of improving survival for children and adults with metastatic disease.
-
Targeting OST Redundancy to Treat Osteosarcoma
A study in people with advanced bone cancer to see if new OST-targeting drugs can slow or stop tumor growth.
-
Focal Adhesion Kinase inhibitor to block osteosarcoma spread to the lungs
A cancer treatment plan tests whether blocking a specific cell signal can stop osteosarcoma from growing and spreading to the lungs in kids and young people.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.